NeuroPace, Inc. (NPCE) Discusses FDA Feedback on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy Transcript

Operator

Greetings, and welcome to the NeuroPace IGE PMA Supplement Update Call. [Operator Instructions] Please note, this conference is being recorded.

I will now turn the call over to Scott Schaper, Head of Investor Relations. Please go ahead.

Scott Schaper
Head of Investor Relations

Good afternoon, and thank you for joining today’s conference call. On the call, you will hear from Joel Becker, NeuroPace’s President and Chief Executive Officer; and Dr. Martha Morrell, NeuroPace’s Chief Medical Officer. Patrick Williams, NeuroPace’s Chief Financial Officer, is also on the line.

Earlier today, NeuroPace issued a press release providing an update on the status of the company’s PMA Supplement seeking to expand the indication for the RNS System to include patients with antiseizure medication-resistant idiopathic generalized epilepsy or IGE. A copy of the press release is available on the Investor Relations section of our website.

Before we begin, I would like to remind you that certain statements made on today’s call may constitute forward-looking statements within the meaning of federal securities laws. These statements include, among others, comments regarding our expectations and beliefs with respect to regulatory matters, including FDA review of our PMA supplement through IGE, our submission issue request